Earnings Play: Agilent Technologies

Upside breakout from a short-term falling wedge pattern.

Stocks (2)

On Monday, after market, Agilent Technologies (A) is anticipated to release fourth quarter EPS of $0.92 compared to $0.89 a year ago on revenue of approximately $1.4 billion, in line with last year. Agilent is an international life sciences and diagnostics company, and on November 13th, the Co announced that it received approval from the U.S. Food and Drug Administration (FDA) for the use of its PD-L1 IHC 22C3 pharmDx as a diagnostic aid in the identification of triple-negative breast cancer and other conditions. 

Technically speaking, on a daily chart, Agilent's stock price has been in a strong uptrend since mid-March. Today, price opened above the upper trendline of a short-term falling wedge pattern that price has been declining within since November 9th, after the stock made a record high of 117.50. The simple moving averages (SMA) are set-up in a bullish manner, with the 20-day SMA above the 50-day SMA and the 50-day SMA above the 200-day SMA. The RSI is over 50 and pointing upwards. Price will likely advance towards its all-time high of 117.50. If price can breakout to the upside of 117.50, then its next target would be 132.75. If price retreats then investors should look for a rebound off of 100.50. If price breaks out below 100.50 it would be a bearish signal that could send price tumbling back to 93.00.         



Source: GAIN Capital, TradingView

More from Earnings

From time to time, GAIN Capital Australia Pty Ltd (“we”, “our”) website may contain links to other sites and/or resources provided by third parties. These links and/or resources are provided for your information only and we have no control over the contents of those materials, and in no way endorse their content. Any analysis, opinion, commentary or research-based material on our website is for information and educational purposes only and is not, in any circumstances, intended to be an offer, recommendation or solicitation to buy or sell. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. No representation or warranty is made, express or implied, that the materials on our website are complete or accurate. We are not under any obligation to update any such material.

As such, we (and/or our associated companies) will not be responsible or liable for any loss or damage incurred by you or any third party arising out of, or in connection with, any use of the information on our website (other than with regards to any duty or liability that we are unable to limit or exclude by law or under the applicable regulatory system) and any such liability is hereby expressly disclaimed.